Company search
Overview
Performance
Portfolio
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Data as at: 12/05/2025
In
Objective
To achieve long-term capital growth by investing in biotechnology and other life sciences companies.
AIC sector
Management group
Company website
Launch date
06/05/1994
August
Domicile
United Kingdom
Fund manager
Ailsa Craig, Marek Poszepczynski
Dividend frequency
Semi-Annually
Wind-up provisions
The Association Articles of the company provide for Directors to put forward a proposal for the continuation of the company at the AGM at two-yearly intervals. The upcoming continuation vote is scheduled for the December 2025 AGM.
Continuation vote
2 yearly
| Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
|---|---|---|---|---|---|---|---|---|
| 202.84 | 267.21 | 578.00 | 654.33 | -11.66 | 6 | 4.91 | Jul, Dec | 1.2 (31/08/2024) |
Scroll
Dividends
Dividends declared in last 12 months
| Ex-dividend date | Payment date | Dividend amount | Special dividend | Financial year |
|---|---|---|---|---|
| 19/12/2024 | 24/01/2025 | 15.560 | No | 2025 |
| 25/07/2024 | 23/08/2024 | 14.500 | No | 2024 |
Scroll
Performance (%)
| Return type | 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|---|
| International Biotechnology | Share price total return | -5.6 | 14.1 | 1.0 | 52.7 |
| Biotechnology & Healthcare AIC sector | Share price total return | -17.2 | -10.5 | -23.1 | 34.4 |
Scroll
Share structure
Number of shares
35,093,700
6,290,117
Traded volumes (number of shares)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 184,842 | 1,578,829 | 19,493,336 | 84,318,549 |
| Average | N/A | 87,713 | 77,049 | 66,866 |
Scroll
Traded values (m)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 1.07 | 9.20 | 129.09 | 588.03 |
| Average | N/A | 0.51 | 0.51 | 0.47 |
Scroll
Trading details
Top holdings
Data as at : 30/04/2025
| Investment | % of total assets |
|---|---|
| Ascendis Pharma AS ADR | 6.2 |
| Cytokinetics Inc | 4.6 |
| Sv Bcof | 4.4 |
| Travere Therapeutics Inc Ordinary Shares | 4.2 |
| Sv Fund Vi Investment | 4.1 |
| uniQure NV | 4.1 |
| KalVista Pharmaceuticals Inc | 3.6 |
| Biomarin Pharmaceutical Inc | 3.5 |
| Madrigal Pharmaceuticals Inc | 3.5 |
| Scb Sholo211123b 22-Apr-2024 6.47% 22-May-2024 | -17.2 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
